The Effect of Covid-19 on AML Treatment | CheckRare
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma explains how acute myeloid leukemia (AML) patients have been affected by the Covid-19 pandemic.
Related Articles
Managing Cardiomyopathies in Lysosomal Disorders
Dr Ozlem Goker-Alpan and Dr John Jefferies discuss the role of the cardiologist and best practices for managing Lysosomal Disorders
Gene Therapy for Sickle Cell Disease Likely Cost-Effective at
Incremental cost-effectiveness ratios were $126,000 and $281,000 per QALY for two simulation models from a societal perspective.
Marstacimab in Patients with Hemophilia A or B
Davide Martino, discusses the BASIS clinical trial, a phase 3 study testing marstacimab in patients with hemophilia without inhibitors.
Cutaneous T-Cell Lymphoma
Cutaneous T-cell lymphoma (CTCL) belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders.
Treatments for Biliary Tract Cancer
Robin Kate Kelley, MD, Professor of Clinical Medicine Hematology/IOncology, University of California, San Francisco, describes the need for better treatment plans for patients with biliary…
Myasthenia Gravis Treatment Options
Kimberly Moran, PhD, MBA, Head of US Rare Diseases at UCB, discuses new treatment options for myasthenia gravis,
Survival 21 Percent a Year After ICU Discharge for Blood Cancer Patients
For hematologic malignancy (HM) patients admitted to the ICU, survival is 49 percent at seven days and 21 percent at 12 months.